Q3 2025 · 13F-HR
Octagon Capital Advisors LPholdings as filed
Filed 2025-11-14 · accession 0001839435-25-000010
$659.8M
Reported value
27
Positions
2025-09-30
Period end
The Brief · Octagon Capital Advisors LP · Q3 2025
AI · grounded in 13F
Octagon Capital Advisors LP established a new position in ABIVAX SA ABVX valued at $112.5M. The fund also initiated new stakes in DIANTHUS THERAPEUTICS INC DNTH for $95.1M and GOSSAMER BIO INC GOSS for $44.8M. Other new additions include COGENT BIOSCIENCES INC COGT and ARRIVENT BIOPHARMA INC AVBP.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 00370M103 | ABVX | ABIVAX SA | $112.5M | 17.1% | 1,325,000 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $95.1M | 14.4% | 2,416,667 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $44.8M | 6.80% | 17,050,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $41.3M | 6.26% | 2,874,111 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $36.4M | 5.51% | 1,971,054 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $30.7M | 4.65% | 2,624,000 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $29.7M | 4.49% | 9,067,500 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $29.0M | 4.40% | 308,000 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $25.8M | 3.90% | 2,815,000 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $25.1M | 3.81% | 2,130,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $20.4M | 3.10% | 903,500 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $20.4M | 3.09% | 360,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $20.1M | 3.05% | 830,000 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $19.2M | 2.90% | 200,000 | CALL | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $18.0M | 2.73% | 722,595 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $15.5M | 2.35% | 1,273,333 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $14.1M | 2.14% | 1,115,000 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $12.1M | 1.83% | 1,043,110 | Common | SOLE |
| 23306J309 | DBVT | DBV TECHNOLOGIES S A | $10.2M | 1.54% | 1,018,021 | Common | SOLE |
| 67080N101 | NUVB | NUVATION BIO INC | $9.7M | 1.48% | 2,633,334 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $9.6M | 1.45% | 100,000 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $4.6M | 0.70% | 177,667 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $4.4M | 0.66% | 252,000 | Common | SOLE |
| 90466Y202 | UNCY | UNICYCIVE THERAPEUTICS INC | $4.4M | 0.66% | 1,000,000 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $3.2M | 0.49% | 700,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $3.2M | 0.49% | 115,000 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $385,214 | 0.06% | 104,112 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.